CD22 EXON 12 deletion as a pathogenic mechanism of human B-precursor leukemia

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 39, 2010, Pages 16852-16857

  Uckun, Fatih M ^a,b,c   Goodman, Patricia ^d   Ma, Hong ^a,b   Dibirdik, Ilker ^b,c   Qazi, Sanjive ^e  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b CHILDREN S HOSPITAL LOS ANGELES   (United States)

^c PARKER HUGHES INSTITUTE   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e GUSTAVUS ADOLPHUS COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD22 ANTIGEN; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; MESSENGER RNA; CD22 PROTEIN, HUMAN; RNA PRECURSOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B CELL LEUKEMIA; B CELL LYMPHOMA; DNA MICROARRAY; EXON; FRAMESHIFT MUTATION; GENE CONTROL; GENE DELETION; GENE EXPRESSION; GENE SEQUENCE; GENETIC VARIABILITY; HAIRY CELL LEUKEMIA; HOMOZYGOSITY; HUMAN; HUMAN CELL; INFANT; LEUKEMIA CELL; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRE B LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN SECONDARY STRUCTURE; RNA SPLICING; RNA STABILITY; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR SUPPRESSOR GENE; UPREGULATION; ALTERNATIVE RNA SPLICING; ANIMAL; CHEMISTRY; CONFORMATION; GENE EXPRESSION REGULATION; GENETICS; MOLECULAR GENETICS; TRANSGENIC MOUSE;

MUS; MUS MUSCULUS;

ALTERNATIVE SPLICING; ANIMALS; BASE SEQUENCE; EXONS; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; INFANT; MICE; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; NUCLEIC ACID CONFORMATION; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RNA PRECURSORS; SEQUENCE DELETION; SIALIC ACID BINDING IG-LIKE LECTIN 2;

EID: 78049276263     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1007896107     Document Type: Article

References (62)

1. Chaouchi N, Vazquez A, Galanaud P, Leprince C (1995) B cell antigen receptor-mediated apoptosis. Importance of accessory molecules CD19 and CD22, and of surface IgM cross-linking. J Immunol 154:3096-3104.
2. Doody GM, et al. (1995) A role in B cell activation for CD22 and the protein tyrosine phosphatase SHP. Science 269:242-244.
3. Sato S, et al. (1996) CD22 is both a positive and negative regulator of B lymphocyte antigen receptor signal transduction: altered signaling in CD22-deficient mice. Immunity 5:551-62. (Pubitemid 27062065)
4. Stoddart A, Ray RJ, Paige CJ (1997) Analysis of murine CD22 during B cell development: CD22 is expressed on B cell progenitors prior to IgM. Int Immunol 9:1571-1579. (Pubitemid 27434690)
5. Tuscano JM, Riva A, Toscano SN, Tedder TF, Kehrl JH (1999) CD22 cross-linking generates B-cell antigen receptor-independent signals that activate the JNK/SAPK signaling cascade. Blood 94:1382-1392. (Pubitemid 29380419)
6. Tedder TF, Poe JC, Haas KM (2005) CD22: A multifunctional receptor that regulates B lymphocyte survival and signal transduction. Adv Immunol 88:1-50.
7. Songyang Z, et al. (1993) SH2 domains recognize specific phosphopeptide sequences. Cell 72:767-78. (Pubitemid 23093884)
8. Law CL, et al. (1996) CD22 associates with protein tyrosine phosphatase 1C, Syk, and phospholipase C-gamma(1) upon B cell activation. J Exp Med 183:547-60.
9. Tuscano JM, Engel P, Tedder TF, Agarwal A, Kehrl JH (1996) Involvement of p72syk kinase, p53/56lyn kinase and phosphatidyl inositol-3 kinase in signal transduction via the human B lymphocyte antigen CD. Eur J Immunol 26:1246-52. (Pubitemid 26001057)
10. Cornall RJ, et al. (1998) Polygenic autoimmune traits: Lyn, CD22 and SHP-1 are limiting elements of a biochemical pathway regulating BCR signaling and selection. Immunity 8:497-508.
11. Blasioli J, Paust S, Thomas ML (1999) Definition of the sites of interaction between the protein tyrosine phosphatase SHP-1 and CD. J Biol Chem 274:2303-2307.
12. Tybulewicz VLJ (1998) Analysis of antigen receptor signalling using mouse gene targeting. Curr Opin Cell Biol 10:195-204. (Pubitemid 28174762)
13. Tsui HW, Siminovitch KA, de Souza L, Tsui FW (1993) Motheaten and viable motheaten mice have mutations in the haematopoietic cell phosphatase gene. Nat Genet 4:124-129. (Pubitemid 23179093)
14. Hibbs ML, et al. (1995) Multiple defects in the immune system of Lyn-deficient mice, culminating in autoimmune disease. Cell 83:301-311.
15. O'Keefe TL, Williams GT, Davies SL, Neuberger MS (1996) Hyperresponsive B cells in CD22-deficient mice. Science 274:798-801.
16. Otipoby KL, et al. (1996) CD22 regulates thymus-independent responses and the lifespan of B cells. Nature 384:634-7.
17. Wang J, Koizumi T, Watanabe T (1996) Altered antigen receptor signaling and impaired Fas-mediated apoptosis of B cells in Lyn-deficient mice. J Exp Med 184:831-838.
18. Ostrakhovitch EA, Wang Y, Li SS (2009) SAP binds to CD22 and regulates B cell inhibitory signaling and calcium flux. Cell Signal 21:540-50.
19. Trigg ME, et al. (2008) Ten-year survival of children with acute lymphoblastic leukemia: A report from the Children's Oncology Group. Leukemia Lymphoma 49:1142-54.
20. Seibel NL, et al. (2008) Early postinduction intensification therapy improves survival for children and adolescents with high risk acute lymphoblastic leukemia: A report from the Chilren's Oncology Group. Blood 111:2548-2555.
21. Stanulla M, Schrappe M (2009) Treatment of childhood acute lymphoblastic leukemia. Semin Hematol 46(1):52-63M.
22. Reaman GH, et al. (1999) Treatment outcome and prognostic factors for infants with acute lymphoblastic leukemia on two consecutive trials of the Children's Cancer Group. J Clin Oncol 17:445-455.
23. Chessels JM, Harrison CJ, Watson SL, Vora AJ, Richards SM (2002) Treatment of infants with lymphoblastic leukemia: Results of the UK Infant Protocols 1987-1999. Brit J Haematol 117:306-314. (Pubitemid 34451145)
24. Kosaka Y, et al. (2004) Infant acute lymphoblastic leukemia with MLL gene rearrangements: outcome following intensive chemotherapy and hematopoietic stem cell transplantation. Blood 104:3527-3534. (Pubitemid 39564423)
25. Hilden JM, et al. (2006) Analysis of prognostic factors of acute lymphoblastic leukemia in infants: Report on CCG 1953 from the Children's Oncology Group. Blood 108:441-451. (Pubitemid 44061340)
26. Tomizawa D, et al. (2009) Outcome of recurrent or refractory acute lymphoblastic leukemia in infants with MLL gene rearrangements: A report from the Japan Infant Leukemia Study Group. Pediatr Blood Cancer 52:808-13.
27. Uckun FM, et al. (1998) Clinical significance of MLL-AF4 fusion transcript expression in the absence of a cytogenetically detectable t (4; 11)(q21; q23) chromosomal translocation. Blood 92:810-821.
28. Sun L, et al. (1999) Expression of dominant-negative and mutant isoforms of the antileukemic transcription factor Ikaros in infant acute lymphoblastic leukemia. Proc Natl Acad Sci USA 96:680-685. (Pubitemid 29061268)
29. Russell T, et al. (2008) Differential expression of Ikaros isoforms in monozygotic twins with MLL-rearranged precursor-B acute lymphoblastic leukemia. J Pediat Hematol Onc 30:941-4.
30. Yamaguchi H, et al. (2009) Multistep pathogenesis of leukemia via the MLL-AF4 chimeric gene/Flt3 gene tyrosine kinase domain (TKD)-mutation-related enhancement of S100A6 expression. Exp Hematol 37:701-714.
31. Brassesco MS, et al. (2009) Cytogenetic and molecular analysis of MLL rearrangements in acute lymphoblastic leukemia survivors. Mutagenesis 24:153-60.
32. Zuna J, et al. (2009) Covert preleukemia driven by MLL gene fusion. Genes Chromosomes Cancer 48:98-107.
33. Chuk MK, McIntyre E, Small D, Brown P (2009) Discordance of MLL-rearranged (MLL-R) infant acute lymphoblastic leukemia in monozygotic twins with spontaneous clearance of preleukemic clone in unaffected twin. Blood 113:6691-6694.
34. Qazi S, Uckun FM (2010) Gene expression profiles of infant acute lymphoblastic leukaemia and its prognostically distinct subsets. Brit J Haematol 149:865-873.
35. Hatta Y, et al. (1999) Identification of the gene variations in human CD22. Immunogenetics 49:280-286. (Pubitemid 29119037)
36. The Wellcome Trust Case Control Consortium (2007) Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447:661-678.
37. Kawamata N, et al. (2008) Molecular allelokaryotyping of pediatric acute lymphoblastic leukemias by high-resolution single nucleotide polymorphism oligonucleotide genomic microarray. Blood 111:776-784.
38. Miyagawa H, et al. (2008) Association of polymorphisms in complement component C3 gene with susceptibility to systemic lupus erythematosus. Rheumatology 47(2):158-64. (Pubitemid 351168224)
39. Mullighan CG, Downing JR Genome-wide profiling of genetic alterations in acute lymphoblastic leukemia: recent insights and future directions. Leukemia 23:1209-1218.
40. Venables JP (2004) Aberrant and alternative splicing in cancer. Cancer Res 64:7647-7654.
41. Hui J, et al. (2005) Intronic CA-repeat and CA-rich elements: a new class of regulators of mammalian alternative splicing. EMBO J 24:1988-1998. (Pubitemid 40896170)
42. Baralle D, Baralle M (2005) Splicing in action: assessing disease causing sequence changes. J Med Genet 42:737-748. (Pubitemid 41475248)
43. Venables JP, et al. (2008) Multiple and specific mRNA processing targets for the major human hnRNP proteins. Mol Cell Biol 28:6033-6043.
44. Hung L, et al. (2008) Diverse roles of hnRNP L in mammalian mRNA processing: A combined microarray and RNAi analysis. RNA 14:284-296. (Pubitemid 351171589)
45. Wang Z, Burge CB (2008) Splicing regulation: From a parts list of regulatory elements to an integrated splicing code. RNA 14:802-813. (Pubitemid 351574901)
46. Pomares E, et al. (2009) Identification of an intronic single-point mutation in RP2 as the cause of semidominant X-linked retinitis pigmentosa. IOVS 50:5107-5114.
47. Davis RL, Homer VM, George PM, Brennan SO (2009) A deep intronic mutation in FGB creates a consensus exonic splicing enhancer motif that results in afibrinogenemia caused by aberrant mRNA splicing, which can be corrected in vitro with antisense oligonucleotide treatment. Hum Mutat 30:221-227.
48. Fogel BL, Lee JY, Perlman S (2009) Aberrant splicing of the senataxin gene in a patient with ataxia with oculomotor apraxia type 2. Cerebellum 8:448-453.
49. Galante PAF, et al. (2009) A comprehensive in silico expression analysis of RNA binding proteins in normal and tumor tissue: Identification of potential players in tumor formation. RNA Biol, eds D Sandhu et al. 6:426-433.
50. Wilson GL, et al. (1993) Genomic structure and chromosomal mapping of the human CD22 Gene. J Immunol 150:5013-5024.
51. Rhodes DR, et al. (2007) Oncomine 3.0: Genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia 9:166-180.
52. Wang K, et al. (2009) Genome-wide identification of post-translational modulators of transcription factor activity in human B cells. Nat Biotechnol 27:829-839.
53. Adams JM, et al. (1985) The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 318:533-538.
54. Seo J, Lozano MM, Dudley JP (2005) Nuclear maxtrix binding regulates SATB1- mediated transcriptional repression. J Biol Chem 280:24600-24609. (Pubitemid 40934548)
55. Greaves MF, Maia AT, Wiemels JL, Ford AM(2003) Leukemia in twins: Lessons in natural history. Blood 102:2321-2333.
56. Kreitman RJ (2009) Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies. BioDrugs 23(1):1-13 10.2165/ 00063030-200923010-00001.
57. Wayne AS, et al. (2010) Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22- positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial. Clin Cancer Res 16:1894-903.
58. Takeshita A, et al. (2009) CMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cells. Leukemia 23:1329-36.
59. Quintás-Cardama A, Wierda W, O'Brien S (2010) Investigational immunotherapeutics for B-cell malignancies. J Clin Oncol 28:884-92.
60. Chan CT, Wang J, French RR, Glennie MJ (1998) Internalization of the lymphocytic surface protein CD22 is controlled by a novel membrane proximal cytoplasmic motif. J Biol Chem 273:27809-27815. (Pubitemid 28496067)
61. John B, et al. (2003) The B cell coreceptor CD22 associates with AP50, a clathrin-coated pit adapter protein, via tyrosine-dependent interaction. J Immunol 170:3534-43. (Pubitemid 36359220)
62. Shieh JJ, Liu KT, Huang SW, Chen YJ, Hsieh TY (2009) Modification of alternative splicing of Mcl-1 pre-mRNA using antisense morpholino oligonucleotides induces apoptosis in basal cell carcinoma cells. J Invest Dermatol 129:2497-2506.